Skip to content

Study · Observational study · n = 37 · 2016

6 results

Improved diastolic function in type 2 diabetes after a six month liraglutide treatment.

Saponaro F, Sonaglioni A, Rossi A, Montefusco L, Lombardo M, Adda G, Arosio M

Diabetes research and clinical practice4 May 2016Cited by 34 (Europe PMC)

PMID27485853 (opens in a new tab)DOI10.1016/j.diabres.2016.04.046 (opens in a new tab)PepBankPUB-27485853
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, HbA1c fell with liraglutide, and the fall was similar to the control group on other therapies.

    In plain wordsIn adults with type 2 diabetes, blood sugar control improved with liraglutide, about the same as with other diabetes treatments.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c change
    Study

    n = 37

    Comparator
    Control group on other hypoglycaemic therapies
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −1.5%
    liraglutide
    HbA1c change
    −1.3%
    control

    Source sentences

    Summary
    Glucose control improved similarly in both groups: HA1bc -1.5% (-17mmol/mol) vs -1.3% (-14mmol/mol), p=0.67.
    2 context sentences
    Summary · context
    Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6months.
    Summary · context
    Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6months.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, e-lat increased from baseline after 6 months of liraglutide.

    In plain wordsIn adults with type 2 diabetes, a heart relaxation measure improved after 6 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseEarly diastolic mitral annulus velocity, lateral (e-lat)
    Study

    n = 26

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    e-lat baseline
    9.2 cm/s
    liraglutide
    e-lat 6 months
    11.6 cm/s
    liraglutide

    Source sentences

    Summary
    In the liraglutide group the early diastolic mitral annulus velocity on the lateral (e-lat) and medial (e-med) sides of the mitral annulus increased from 9.2±3.4 to 11.6±4.7cm/s (p<0.001) and from 6.9±1.7 to 8.4±2.6cm/s (p<0.003), respectively.
    2 context sentences
    Summary · context
    Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6months.
    Summary · context
    Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6months.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, e-med increased from baseline after 6 months of liraglutide.

    In plain wordsIn adults with type 2 diabetes, a second heart relaxation measure improved after 6 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseEarly diastolic mitral annulus velocity, medial (e-med)
    Study

    n = 26

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    e-med baseline
    6.9 cm/s
    liraglutide
    e-med 6 months
    8.4 cm/s
    liraglutide

    Source sentences

    Summary
    In the liraglutide group the early diastolic mitral annulus velocity on the lateral (e-lat) and medial (e-med) sides of the mitral annulus increased from 9.2±3.4 to 11.6±4.7cm/s (p<0.001) and from 6.9±1.7 to 8.4±2.6cm/s (p<0.003), respectively.
    2 context sentences
    Summary · context
    Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6months.
    Summary · context
    Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6months.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the lateral early-to-late velocity ratio increased from baseline after 6 months of liraglutide.

    In plain wordsIn adults with type 2 diabetes, a heart filling ratio improved after 6 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseEarly-to-late velocity ratio, lateral mitral annulus
    Study

    n = 26

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Early-to-late ratio baseline
    0.7 ratio
    lateral
    Early-to-late ratio 6 months
    0.9 ratio
    lateral

    Source sentences

    Summary
    The ratio of early-to-late velocities on the lateral and medial sides of the mitral annulus increased from 0.7±0.3 to 0.9±0.4 (p<0.001) and from 0.5±0.1 to 0.6±0.1 (p<0.02), respectively.
    2 context sentences
    Summary · context
    Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6months.
    Summary · context
    Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6months.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the medial early-to-late velocity ratio increased from baseline after 6 months of liraglutide.

    In plain wordsIn adults with type 2 diabetes, a second heart filling ratio improved after 6 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseEarly-to-late velocity ratio, medial mitral annulus
    Study

    n = 26

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Early-to-late ratio baseline
    0.5 ratio
    medial
    Early-to-late ratio 6 months
    0.6 ratio
    medial

    Source sentences

    Summary
    The ratio of early-to-late velocities on the lateral and medial sides of the mitral annulus increased from 0.7±0.3 to 0.9±0.4 (p<0.001) and from 0.5±0.1 to 0.6±0.1 (p<0.02), respectively.
    2 context sentences
    Summary · context
    Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6months.
    Summary · context
    Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6months.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the ratio of early mitral inflow to early myocardial relaxation velocity decreased from baseline after 6 months of liraglutide.

    In plain wordsIn adults with type 2 diabetes, a heart filling pressure measure fell after 6 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseRatio of early mitral inflow velocity to early myocardial relaxation velocity
    Study

    n = 26

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Inflow-to-relaxation velocity ratio baseline
    10.7 ratio
    liraglutide
    Inflow-to-relaxation velocity ratio 6 months
    8.5 ratio
    liraglutide

    Source sentences

    Summary
    The ratio of early diastolic mitral inflow velocity to early diastolic myocardial relaxation velocity decreased from 10.7±4.3 to 8.5±2.5 (p<0.005).
    2 context sentences
    Summary · context
    Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6months.
    Summary · context
    Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.